Published in Am J Physiol Renal Physiol on February 03, 2010
Metabolomics in the study of kidney diseases. Nat Rev Nephrol (2011) 1.32
Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J Proteome Res (2011) 1.18
Urine metabolomics for kidney cancer detection and biomarker discovery. Urol Oncol (2011) 1.12
Stability of miRNA in human urine supports its biomarker potential. Biomark Med (2013) 1.02
Network analysis of a Pkd1-mouse model of autosomal dominant polycystic kidney disease identifies HNF4α as a disease modifier. PLoS Genet (2012) 0.90
Systematic variations associated with renal disease uncovered by parallel metabolomics of urine and serum. BMC Syst Biol (2012) 0.81
A Metabolomics Profiling Study in Hand-Foot-and-Mouth Disease and Modulated Pathways of Clinical Intervention Using Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry. Evid Based Complement Alternat Med (2013) 0.78
The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. Am J Physiol Renal Physiol (2015) 0.78
Unraveling heterogeneous susceptibility and the evolution of breast cancer using a systems biology approach. Genome Biol (2015) 0.78
Microextraction by Packed Sorbent (MEPS) and Solid-Phase Microextraction (SPME) as Sample Preparation Procedures for the Metabolomic Profiling of Urine. Metabolites (2014) 0.78
Compelling "metabolomic" biomarkers may signal PKD pathogenesis. Am J Physiol Renal Physiol (2010) 0.75
Applications of metabolomics for kidney disease research: from biomarkers to therapeutic targets. Organogenesis (2013) 0.75
Systems biology of polycystic kidney disease: a critical review. Wiley Interdiscip Rev Syst Biol Med (2015) 0.75
KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res (2009) 28.60
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. Nat Genet (2005) 6.67
Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex. Neurochem Res (2004) 4.33
Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet (1994) 3.73
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 3.26
A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal Biochem (2007) 3.14
Peroxisome biogenesis disorders. Biochim Biophys Acta (2006) 3.06
Quality control for plant metabolomics: reporting MSI-compliant studies. Plant J (2008) 2.97
PLS dimension reduction for classification with microarray data. Stat Appl Genet Mol Biol (2004) 2.85
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem (2004) 2.26
SetupX--a public study design database for metabolomic projects. Pac Symp Biocomput (2007) 2.20
Partial least squares proportional hazard regression for application to DNA microarray survival data. Bioinformatics (2002) 2.16
Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol (2008) 1.92
Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol (2006) 1.78
Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics (2008) 1.78
Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer (2006) 1.78
Earlier diagnosis of autosomal dominant polycystic kidney disease: importance of family history and implications for cardiovascular and renal complications. Am J Kidney Dis (2005) 1.55
Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med (2007) 1.54
Evidence for a substrate cycle between AMP and adenosine in isolated hepatocytes. Proc Natl Acad Sci U S A (1983) 1.52
Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int (2007) 1.44
Grade-dependent proteomics characterization of kidney cancer. Mol Cell Proteomics (2009) 1.41
Metabolomics--a new exciting field within the "omics" sciences. Environ Health Perspect (2004) 1.35
Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol (2007) 1.35
Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol (2008) 1.33
Renal epithelial fluid secretion and cyst growth: the role of cyclic AMP. FASEB J (1989) 1.13
Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int (2009) 1.12
p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. BMC Nephrol (2007) 1.11
Metabolomics takes its place as latest up-and-coming "omic" science. J Natl Cancer Inst (2004) 1.08
Allantoin in human plasma, serum, and nasal-lining fluids as a biomarker of oxidative stress: avoiding artifacts and establishing real in vivo concentrations. Antioxid Redox Signal (2009) 1.04
Metabolomics of neural progenitor cells: a novel approach to biomarker discovery. Cold Spring Harb Symp Quant Biol (2008) 1.02
Polycystic kidney diseases: from molecular discoveries to targeted therapeutic strategies. Cell Mol Life Sci (2008) 1.01
S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis. Carcinogenesis (2008) 1.00
Strategies to inhibit cyst formation in ADPKD. Clin J Am Soc Nephrol (2008) 0.99
Metabolomics in biomarker discovery: future uses for cancer prevention. Future Oncol (2008) 0.97
Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease. Nephrology (Carlton) (2007) 0.93
WilcoxCV: an R package for fast variable selection in cross-validation. Bioinformatics (2007) 0.91
Nek8 mutation causes overexpression of galectin-1, sorcin, and vimentin and accumulation of the major urinary protein in renal cysts of jck mice. Mol Cell Proteomics (2005) 0.91
Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.90
Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease. J Renin Angiotensin Aldosterone Syst (2006) 0.89
The fundamental importance of human galactose metabolism: lessons from genetics and biochemistry. Trends Genet (1998) 0.87
New insights into polycystic kidney disease and its treatment. Curr Opin Nephrol Hypertens (1998) 0.87
Unified ultrasonographic diagnostic criteria for polycystic kidney disease. J Am Soc Nephrol (2008) 0.85
Hyperuricemia, gout, and autosomal dominant polycystic kidney disease. Am J Med Sci (1989) 0.83
Serum and urinary biomarker signatures for rapid preclinical in vivo assessment of CDK inhibition as a therapeutic approach for PKD. Cell Cycle (2008) 0.82
Regulation of renal adenosine excretion in humans--role of sodium and fluid homeostasis. Nephrol Dial Transplant (2004) 0.82
A simple quantitative assay for urinary adenosine using column-switching high-performance liquid chromatography. Tohoku J Exp Med (2006) 0.80
Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol (2008) 12.96
Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics (2007) 6.93
Potential of metabolomics as a functional genomics tool. Trends Plant Sci (2004) 4.10
FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Anal Chem (2009) 3.71
Seven Golden Rules for heuristic filtering of molecular formulas obtained by accurate mass spectrometry. BMC Bioinformatics (2007) 3.70
A proposed framework for the description of plant metabolomics experiments and their results. Nat Biotechnol (2004) 3.32
A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal Biochem (2007) 3.14
Metabolomic database annotations via query of elemental compositions: mass accuracy is insufficient even at less than 1 ppm. BMC Bioinformatics (2006) 3.02
Process for the integrated extraction, identification and quantification of metabolites, proteins and RNA to reveal their co-regulation in biochemical networks. Proteomics (2004) 2.81
Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res (2006) 2.68
A prominent role for the CBF cold response pathway in configuring the low-temperature metabolome of Arabidopsis. Proc Natl Acad Sci U S A (2004) 2.64
Differential metabolic networks unravel the effects of silent plant phenotypes. Proc Natl Acad Sci U S A (2004) 2.63
The metabolomics standards initiative. Nat Biotechnol (2007) 2.54
The metabolic signature related to high plant growth rate in Arabidopsis thaliana. Proc Natl Acad Sci U S A (2007) 2.44
Mass-spectrometry-based metabolomics: limitations and recommendations for future progress with particular focus on nutrition research. Metabolomics (2009) 2.21
SetupX--a public study design database for metabolomic projects. Pac Symp Biocomput (2007) 2.20
Natural genetic variation of freezing tolerance in Arabidopsis. Plant Physiol (2006) 2.10
Human gut microbiome adopts an alternative state following small bowel transplantation. Proc Natl Acad Sci U S A (2009) 2.08
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res (2011) 2.07
CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol (2012) 2.05
Metabolite profiling of human colon carcinoma--deregulation of TCA cycle and amino acid turnover. Mol Cancer (2008) 2.02
Sources of variation in Affymetrix microarray experiments. BMC Bioinformatics (2005) 1.94
Analysis of highly polar compounds of plant origin: combination of hydrophilic interaction chromatography and electrospray ion trap mass spectrometry. Anal Biochem (2002) 1.93
Systems rebalancing of metabolism in response to sulfur deprivation, as revealed by metabolome analysis of Arabidopsis plants. Plant Physiol (2005) 1.89
Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res (2012) 1.81
LipidBlast in silico tandem mass spectrometry database for lipid identification. Nat Methods (2013) 1.78
Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol (2006) 1.78
Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics (2008) 1.78
Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer (2006) 1.78
Advances in structure elucidation of small molecules using mass spectrometry. Bioanal Rev (2010) 1.76
Hierarchical metabolomics demonstrates substantial compositional similarity between genetically modified and conventional potato crops. Proc Natl Acad Sci U S A (2005) 1.75
Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in apolipoprotein E-/- mice. Arterioscler Thromb Vasc Biol (2011) 1.75
Identification of metabolic and biomass QTL in Arabidopsis thaliana in a parallel analysis of RIL and IL populations. Plant J (2007) 1.74
How large is the metabolome? A critical analysis of data exchange practices in chemistry. PLoS One (2009) 1.73
CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest (2011) 1.71
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2013) 1.66
Exogenous attenuation of p21(Waf1/Cip1) decreases mesangial cell hypertrophy as a result of hyperglycemia and IGF-1. J Am Soc Nephrol (2004) 1.65
Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol (2002) 1.63
Metabolite profiling of Chlamydomonas reinhardtii under nutrient deprivation. Plant Physiol (2005) 1.62
Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med (2010) 1.62
Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care (2007) 1.60
MetaMapp: mapping and visualizing metabolomic data by integrating information from biochemical pathways and chemical and mass spectral similarity. BMC Bioinformatics (2012) 1.56
The volatile compound BinBase mass spectral database. BMC Bioinformatics (2011) 1.55
The Chemical Translation Service--a web-based tool to improve standardization of metabolomic reports. Bioinformatics (2010) 1.51
Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A (2002) 1.51
Gene expression profiling of aging in multiple mouse strains: identification of aging biomarkers and impact of dietary antioxidants. Aging Cell (2009) 1.44
Monolithic silica-based capillary reversed-phase liquid chromatography/electrospray mass spectrometry for plant metabolomics. Anal Chem (2003) 1.44
High copper selectively alters lipid metabolism and cell cycle machinery in the mouse model of Wilson disease. J Biol Chem (2007) 1.43
Divergent metabolome and proteome suggest functional independence of dual phloem transport systems in cucurbits. Proc Natl Acad Sci U S A (2010) 1.42
Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol (2008) 1.42
Grade-dependent proteomics characterization of kidney cancer. Mol Cell Proteomics (2009) 1.41
Plant metabolomics: the missing link in functional genomics strategies. Plant Cell (2002) 1.37
Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics (2012) 1.34
Metabolomics in the study of kidney diseases. Nat Rev Nephrol (2011) 1.32
Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther (2011) 1.30
Functional analysis of PKD1 transgenic lines reveals a direct role for polycystin-1 in mediating cell-cell adhesion. J Am Soc Nephrol (2003) 1.26
Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol (2003) 1.25
Application of metabolomics to plant genotype discrimination using statistics and machine learning. Bioinformatics (2002) 1.25
Bayesian analyses of multiple epistatic QTL models for body weight and body composition in mice. Genet Res (2006) 1.24
High quality metabolomic data for Chlamydomonas reinhardtii. Plant Methods (2008) 1.23
Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS (2011) 1.23
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol Cancer Ther (2009) 1.22
Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PLoS One (2012) 1.22
Applications of metabolomics in agriculture. J Agric Food Chem (2006) 1.20
Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J Clin Invest (2009) 1.20
Metabolomics as a Hypothesis-Generating Functional Genomics Tool for the Annotation of Arabidopsis thaliana Genes of "Unknown Function". Front Plant Sci (2012) 1.17
PlantMetabolomics.org: a web portal for plant metabolomics experiments. Plant Physiol (2010) 1.15
Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer (2011) 1.14
Can we discover novel pathways using metabolomic analysis? Curr Opin Biotechnol (2002) 1.14
Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol (2010) 1.12
Urine metabolomics for kidney cancer detection and biomarker discovery. Urol Oncol (2011) 1.12
System response of metabolic networks in Chlamydomonas reinhardtii to total available ammonium. Mol Cell Proteomics (2012) 1.11
p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. BMC Nephrol (2007) 1.11
An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther (2003) 1.11
Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study. BMC Genomics (2012) 1.10
Individual variation in lipidomic profiles of healthy subjects in response to omega-3 Fatty acids. PLoS One (2013) 1.10
Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One (2013) 1.10
Qualitative analysis of algal secretions with multiple mass spectrometric platforms. J Chromatogr A (2012) 1.10
HDBStat!: a platform-independent software suite for statistical analysis of high dimensional biology data. BMC Bioinformatics (2005) 1.10
Statistical methods for comparing comprehensive two-dimensional gas chromatography-time-of-flight mass spectrometry results: metabolomic analysis of mouse tissue extracts. J Chromatogr A (2005) 1.10
Heterosis manifestation during early Arabidopsis seedling development is characterized by intermediate gene expression and enhanced metabolic activity in the hybrids. Plant J (2012) 1.09
Metabolomics Standards Workshop and the development of international standards for reporting metabolomics experimental results. Brief Bioinform (2006) 1.09
Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations. Metabolomics (2012) 1.09
Changes in the proteomic and metabolic profiles of Beta vulgaris root tips in response to iron deficiency and resupply. BMC Plant Biol (2010) 1.09
Characterization of epistasis influencing complex spontaneous obesity in the BSB model. Genetics (2004) 1.07
New opportunities from the cancer metabolome. Clin Chem (2012) 1.06
Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med (2012) 1.06
Metabolomic and transcriptomic analysis of the rice response to the bacterial blight pathogen Xanthomonas oryzae pv. oryzae. Metabolomics (2010) 1.06
Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. Anal Bioanal Chem (2013) 1.05
Motor deficits on a ladder rung task in male and female adolescent and adult CGG knock-in mice. Behav Brain Res (2011) 1.04
Impact of genetics and environment on the metabolite composition of maize grain. J Agric Food Chem (2010) 1.04
Application of liquid chromatography-mass spectrometry analysis in metabolomics: reversed-phase monolithic capillary chromatography and hydrophilic chromatography coupled to electrospray ionization-mass spectrometry. Methods Mol Biol (2007) 1.04
High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers. Cancer Biol Ther (2008) 1.03
Cytosolic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells. Cell Signal (2004) 1.03